Invitae said this week that it completed its acquisition of Singular Bio on June 19.
The cancer diagnostics developer said it was undertaking the reverse stock split in order to meet the Nasdaq's $1 minimum bid price requirement.
The university will use the technology to screen blood samples for certain clinically actionable mutations in non-small cell lung cancer patients.
Precipio said that its ICE COLD-PCR reagents will be sold with PerkinElmer's DNA/RNA extraction and isolation products.
The revenue growth was fueled by continued volume increases in Precipio's pathology services unit, which benefited from a recently expanded sales team.
The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.
The company, which merged with Transgenomic in 2016, attributed the revenue increase to strong demand for its pathology services.
The suit alleged that Precipio failed to meet the obligations of a securities agreement signed by Transgenomic, which it acquired last year.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.